Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833774 | 0.91 | MGLL (0.56) | MGLLNR3C2TP53 | |
| SCHEMBL19971767 | 0.86 | MGLL (0.47) | MGLLNPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL19833992 | 0.86 | MGLL (0.57) | MGLLNR3C2NPC1RAB9ATP53 | |
| SCHEMBL19833805 | 0.84 | MGLL (0.57) | MGLLNR3C2NPC1RAB9ATP53 | |
| SCHEMBL19833794 | 0.84 | MGLL (0.67) | MGLLNR3C2NPC1RAB9A | |
| SCHEMBL19833803 | 0.83 | MGLL (0.79) | MGLLNR3C2 | |
| SCHEMBL19834022 | 0.80 | MGLL (0.49) | MGLLNR3C2ALDH1A1TP53 | |
| SCHEMBL19833872 | 0.79 | MGLL (0.51) | MGLLNR3C2 | |
| SCHEMBL19833904 | 0.79 | MGLL (0.57) | MGLLNR3C2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL19833871 | 0.78 | MGLL (0.79) | MGLLNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | MGLL 129/4885NR3C2 2434/4885NPC1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.